GO:0038170 somatostatin signaling pathway: Neuroendocrine Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038170 (somatostatin signaling pathway) is a G protein-coupled receptor signaling pathway initiated by somatostatin binding to a somatostatin receptor (SSTR) and ending with regulation of a downstream cellular process such as transcription.
• Somatostatin (SST), also known as somatotrophin release inhibiting factor (SRIF), is a neuropeptide that acts through five SSTR subtypes (SSTR1-SSTR5) to inhibit secretion, proliferation and motility in many tissues.
• The pathway controls diverse physiology including colonic mucus production via SSTR5-Notch-Hes1, central food intake regulation, pancreatic islet function, and sociability-related circuits in the brain.
• Dysregulation of somatostatin signaling is implicated in pancreatic cancer EMT and TGF-beta/Smad signaling, gestational diabetes-induced glucose intolerance in offspring, and autism-spectrum-related social behavior.
• Key research methods include CRISPR knockout/knock-in of SSTR genes, RNA-seq, phosphoproteomics, and neuropeptide-based pharmacological rescue in animal models.
• EDITGENE provides CRISPR cell model services (KO, point mutation, knock-in, overexpression) and library screening/bioinformatics tailored to somatostatin signaling research.
Description
The somatostatin signaling pathway (GO:0038170) is a biological process in which the neuropeptide somatostatin (SST), also called somatotrophin release inhibiting factor (SRIF), binds to a somatostatin receptor (SSTR) and triggers a G protein-coupled receptor signaling cascade that ultimately regulates downstream cellular processes such as transcription. Somatostatin was originally identified as a hypothalamic inhibitor of growth hormone release, but it is now recognized as a widespread regulator of endocrine, gastrointestinal, immune and neural functions. Because the pathway is initiated by ligand-receptor interaction and converges on gene expression and secretion, it is a paradigm for neuropeptide-mediated GPCR signaling in health and disease. Researchers study GO:0038170 to understand how a single peptide can exert context-dependent effects across tissues. In the colon, somatostatin stimulates MUC2 expression through an SSTR5-Notch-Hes1 axis, linking neuroendocrine signaling to mucosal barrier function. In the brain, central somatostatin signaling regulates food intake and energy balance, and somatostatin receptors are widely expressed in distinct neuronal populations. In the pancreas, an epigenetically regulated GABA-somatostatin circuit underlies gestational diabetes-induced glucose intolerance in offspring. These examples illustrate why the pathway is relevant to metabolic disease, cancer and neurodevelopmental disorders. This article integrates the QuickGO definition of GO:0038170 with verified PubMed literature to summarize the mechanism, key genes, disease links, and experimental strategies including CRISPR-based models. It is intended for researchers who need a concise, citable overview of somatostatin signaling and its tractable experimental systems.
somatostatin signaling pathway At A Glance
| GO ID | GO:0038170 |
|---|---|
| GO term | somatostatin signaling pathway |
| Ontology | biological_process |
| Synonym | somatostatin-activated somatostatin receptor signaling pathway; somatostatin-mediated signaling pathway; somatostatin signalling pathway; somatotrophin release inhibiting factor signaling pathway; SRIF signaling pathway; SST signaling pathway |
| Major function | G protein-coupled receptor signaling initiated by somatostatin binding to SSTR, regulating downstream cellular processes such as transcription |
| Ligand | Somatostatin (SST/SRIF), a neuropeptide |
| Receptors | Somatostatin receptors SSTR1-SSTR5, members of the GPCR superfamily |
| Tissue distribution | Widely expressed in brain, pancreas, gastrointestinal tract and other neuroendocrine tissues |
| Downstream examples | SSTR5-Notch-Hes1-MUC2 in colon; TGF-beta/Smad in pancreatic cancer; GABA-somatostatin circuit in pancreas |
What Is GO:0038170?
GO:0038170 (somatostatin signaling pathway) is defined as a G protein-coupled receptor signaling pathway initiated by somatostatin binding to a somatostatin receptor (SSTR), and ending with the regulation of a downstream cellular process, e.g. transcription. In other words, it covers the molecular events from ligand-receptor engagement through intracellular signal transduction to changes in cell behavior or gene expression.
Why Is somatostatin signaling pathway Important in Cell Biology?
GO:0038170 is important because somatostatin signaling is a central neuroendocrine brake that modulates hormone secretion, gastrointestinal function, neuronal excitability and cell proliferation. Its dysfunction or dysregulation contributes to metabolic disorders such as gestational diabetes-associated glucose intolerance in offspring, to cancer progression including pancreatic cancer epithelial-mesenchymal transition, and to neurodevelopmental phenotypes such as impaired sociability in autism models. Because the pathway is druggable at the receptor level and genetically tractable, it serves as a model for understanding GPCR-mediated transcriptional regulation and for developing targeted therapies.
• Regulates hormone secretion and growth hormone release as a classic hypothalamic inhibitory peptide.
• Controls food intake and energy balance through central somatostatin signaling.
• Modulates colonic mucus barrier via SSTR5-Notch-Hes1-MUC2 signaling.
• Influences pancreatic islet function and glucose homeostasis, with epigenetic programming in gestational diabetes.
• Suppresses epithelial-mesenchymal transition in pancreatic cancer cells via TGF-beta/Smad.
• Shapes social behavior and is implicated in autism-spectrum phenotypes in mouse models.
• Provides a paradigm for GPCR-mediated transcriptional regulation through five SSTR subtypes.
• Offers druggable targets (somatostatin analogs, SSTR agonists/antagonists) for neuroendocrine tumors and metabolic disease.
• Enables CRISPR-based dissection of receptor-specific functions in vitro and in vivo.
• Connects neuropeptide biology to mucosal immunity, cancer and neurodevelopment.
What Happens During somatostatin signaling pathway?
Ligand binding and receptor activation
In simple terms: Somatostatin acts like a key that fits into specific locks (SSTRs) on the cell surface.
The pathway begins when somatostatin (SST/SRIF) binds to one of five somatostatin receptors (SSTR1-SSTR5), which are G protein-coupled receptors. This binding induces a conformational change in the receptor that activates heterotrimeric G proteins, typically Gi/Go, leading to inhibition of adenylyl cyclase and reduced cAMP levels. Receptor activation is the committed step of GO:0038170 and determines which downstream cellular process is regulated.
Intracellular signal transduction
In simple terms: Once the receptor is activated, it sends signals inside the cell that change what the cell does.
Activated SSTRs modulate multiple intracellular effectors, including adenylyl cyclase, ion channels, and protein kinases. Depending on the receptor subtype and cell context, signaling can inhibit secretion, reduce proliferation, or alter gene transcription. In pancreatic cancer cells, somatostatin inhibits epithelial-mesenchymal transition by mediating the TGF-beta/Smad signaling pathway. In the colon, SSTR5 activation engages Notch-Hes1 signaling to stimulate MUC2 expression.
Regulation of downstream cellular processes
In simple terms: The signal ends by changing how the cell behaves, such as turning genes on or off.
The terminal step of GO:0038170 is regulation of a downstream cellular process, often transcription. For example, somatostatin-stimulated SSTR5 signaling increases MUC2 transcription through Notch-Hes1 in colonic cells. In the brain, somatostatin signaling modulates neuronal excitability and behavior, including sociability circuits in autism models. In pancreatic islets, an epigenetically regulated GABA-somatostatin circuit affects glucose homeostasis in offspring.
Tissue-specific outcomes
In simple terms: The same signal can do different things in different organs.
In the hypothalamus, somatostatin inhibits growth hormone release. In the gastrointestinal tract, it regulates motility and mucus production. In the pancreas, it modulates insulin and glucagon secretion and is involved in gestational diabetes-induced glucose intolerance. In the central nervous system, it regulates food intake and social behavior. This pleiotropy is a hallmark of somatostatin signaling and a key reason for studying GO:0038170 in multiple model systems.
Key Genes Involved in GO:0038170 somatostatin signaling pathway
The following genes and proteins are central to somatostatin signaling (GO:0038170) and are commonly studied using CRISPR and other functional genomics approaches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SST | Encodes somatostatin neuropeptide ligand | Ligand for all SSTRs; knockout alters hormone secretion and behavior |
| SSTR1 | Somatostatin receptor subtype 1 | Mediates Gi-coupled signaling; subtype-specific functions |
| SSTR2 | Somatostatin receptor subtype 2 | Target of somatostatin analogs; regulates secretion and proliferation |
| SSTR3 | Somatostatin receptor subtype 3 | Expressed in brain; modulates neuronal excitability |
| SSTR4 | Somatostatin receptor subtype 4 | Involved in pain and inflammation signaling |
| SSTR5 | Somatostatin receptor subtype 5 | Mediates SSTR5-Notch-Hes1-MUC2 in colon |
| NOTCH1 | Notch receptor | Downstream of SSTR5 in colonic MUC2 regulation |
| HES1 | Notch effector transcription factor | Mediates somatostatin-stimulated MUC2 expression |
| MUC2 | Mucin 2, major colonic mucin | Readout of SSTR5-Notch-Hes1 signaling |
| TGFB1 | Transforming growth factor beta 1 | Linked to somatostatin inhibition of EMT in pancreatic cancer |
| SMAD2/3 | TGF-beta signaling effectors | Mediate somatostatin effects on EMT |
| GAD1/GAD2 | GABA synthesis enzymes | Part of GABA-somatostatin circuit in pancreas |
| GABRA/GABRB | GABA receptor subunits | Modulate somatostatin signaling in islets |
| CREB1 | cAMP response element binding protein | Downstream transcription factor for GPCR signaling |
| SSTR2/SSTR5 | Receptor heterodimers | Potential for subtype-selective targeting |
| SST interneurons | Cortical and hippocampal interneuron subtypes | Regulate network excitability and sociability |
How Is somatostatin signaling pathway Regulated?
Somatostatin signaling is regulated at multiple levels. Ligand availability is controlled by SST gene expression and secretion, which respond to metabolic and neural cues. Receptor levels and subtype composition are regulated transcriptionally and epigenetically; for example, an epigenetically regulated GABA-somatostatin circuit underlies gestational diabetes-induced glucose intolerance in offspring. Receptor desensitization and internalization following agonist binding provide short-term feedback. Downstream, the pathway intersects with Notch-Hes1 and TGF-beta/Smad signaling, which can modulate the strength and duration of the response. In the brain, somatostatin interneuron activity is regulated by neuropeptide inputs and contributes to circuit-level control of behavior.
somatostatin signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SSTR5 | Colonic mucus barrier and MUC2 expression | SSTR5 knockout colonic epithelial cells; Notch-Hes1 reporter |
| SST | Gestational diabetes-induced glucose intolerance in offspring | Maternal diet-induced gestational diabetes mouse model; islet-specific SST knockout |
| SSTR2 | Pancreatic cancer EMT and TGF-beta/Smad signaling | Pancreatic cancer cell lines with SSTR2 knockout or overexpression |
| SST interneurons | Autism-related social behavior | Lateral septum neuron manipulation in autism mouse model |
| SSTR1-5 | Central food intake regulation | Hypothalamic-specific receptor knockout or agonist treatment |
Somatostatin signaling in pancreatic cancer
Somatostatin inhibits epithelial-mesenchymal transition (EMT) of pancreatic cancer cells by mediating the TGF-beta/Smad signaling pathway. This suggests that loss of somatostatin signaling may promote invasive phenotypes, and that SSTR agonists could have therapeutic potential in pancreatic cancer. Experimental models include pancreatic cancer cell lines with SSTR knockout or overexpression and TGF-beta/Smad reporters.
Gestational diabetes and offspring glucose intolerance
Epigenetically regulated pancreatic GABA-somatostatin signaling underlies gestational diabetes-induced glucose intolerance in offspring. This implicates somatostatin signaling in developmental programming of metabolic disease and suggests that targeting the GABA-somatostatin circuit may improve glucose homeostasis in offspring. Relevant models include maternal diet-induced gestational diabetes in rodents and pancreatic islet-specific genetic manipulations.
Neurodevelopmental and social behavior disorders
Neuropeptide therapeutics targeting lateral septum neurons can repress circuits that disable sociability in an autism mouse model, highlighting the role of somatostatin signaling in social behavior. Somatostatin receptors are widely expressed in the brain, and central somatostatin signaling regulates food intake. These findings link GO:0038170 to autism-spectrum phenotypes and motivate studies using somatostatin interneuron manipulations.
Gastrointestinal barrier and mucosal disease
Somatostatin stimulates colonic MUC2 expression through the SSTR5-Notch-Hes1 signaling pathway. MUC2 is the major component of the colonic mucus barrier, so dysregulation of this pathway may contribute to mucosal inflammation or barrier dysfunction. Experimental systems include colonic epithelial cell lines and intestinal organoids with SSTR5 or Hes1 knockout.
From somatostatin signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SSTR5 mediate somatostatin-stimulated MUC2 expression? | SSTR5 knockout colonic epithelial cells; MUC2 promoter reporter |
| Does loss of SST in pancreatic islets cause glucose intolerance? | Islet-specific SST knockout mouse; glucose tolerance test |
| Does SSTR2 regulate EMT in pancreatic cancer? | SSTR2 knockout or overexpression in pancreatic cancer cells; TGF-beta/Smad readouts |
| Does somatostatin signaling modulate social behavior? | Somatostatin interneuron-specific knockout or chemogenetic manipulation in autism mouse model |
| Does central somatostatin signaling regulate food intake? | Hypothalamic SSTR knockout or agonist infusion in rodents |
| Does epigenetic regulation of GABA-somatostatin circuit affect offspring metabolism? | Maternal gestational diabetes model with epigenetic editing |
How to Study the somatostatin signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes | Identify genes regulated by somatostatin signaling |
| ATAC-seq | Chromatin accessibility | Detect epigenetic regulation of GABA-somatostatin circuit |
| CRISPR knockout screens | Gene essentiality for pathway | Discover novel regulators of somatostatin signaling |
| Western blot | Protein expression and phosphorylation | Measure TGF-beta/Smad or Notch-Hes1 activation |
| Immunofluorescence | Protein localization and cell morphology | Assess EMT markers or receptor expression |
| Glucose tolerance test | In vivo glucose homeostasis | Evaluate pancreatic somatostatin function |
| Behavioral assays | Social behavior and food intake | Study central somatostatin signaling |
| Neuropeptide infusion | Receptor activation in vivo | Modulate somatostatin signaling in brain circuits |
Transcriptomic and epigenomic profiling
RNA-seq and ATAC-seq can identify transcriptional and chromatin changes downstream of somatostatin signaling. For example, somatostatin-stimulated MUC2 expression via SSTR5-Notch-Hes1 was characterized using gene expression analysis. Epigenetic regulation of the GABA-somatostatin circuit in gestational diabetes was studied using epigenomic approaches.
CRISPR-based genetic screens
Pooled CRISPR knockout screens can identify genes required for somatostatin signaling, such as SSTR subtypes and downstream effectors. This approach is useful for uncovering novel regulators of GO:0038170 in cancer cells or neurons.
Pharmacological and neuropeptide interventions
Somatostatin analogs and receptor-specific agonists/antagonists are used to activate or block the pathway in vitro and in vivo. Neuropeptide therapeutics targeting lateral septum neurons were used to modulate sociability in an autism mouse model. Central somatostatin signaling and food intake were studied using peptide infusions.
Protein-protein interaction and signaling assays
Co-immunoprecipitation, Western blotting and phospho-specific antibodies can measure downstream events such as Smad phosphorylation in pancreatic cancer cells and Notch-Hes1 activation in colonic cells. These methods help define the molecular mechanism of GO:0038170.
How CRISPR Can Be Used to Study GO:0038170 somatostatin signaling pathway
Knockout
CRISPR knockout of SSTR subtypes or SST allows loss-of-function studies of GO:0038170. For example, SSTR5 knockout can test its requirement for somatostatin-stimulated MUC2 expression, and SSTR2 knockout can assess its role in pancreatic cancer EMT. Islet-specific SST knockout can model gestational diabetes-related glucose intolerance.
Point Mutation
Point mutations can dissect receptor domains required for G protein coupling or ligand binding. For example, mutating key residues in SSTR5 could test their role in Notch-Hes1 activation. Such models are valuable for understanding subtype-specific signaling.
Knock-in
Knock-in of fluorescent or epitope tags into SSTR genes enables real-time tracking of receptor localization and trafficking. Tagged SSTR knock-in cells can be used to study receptor internalization and downstream signaling.
Overexpression
Overexpression of SST or SSTRs can amplify pathway activity and sensitize cells to somatostatin. For example, SSTR5 overexpression in colonic cells can enhance MUC2 induction, and SSTR2 overexpression in pancreatic cancer cells can suppress EMT. Overexpression models are useful for gain-of-function screens.
How EDITGENE Supports somatostatin signaling pathway Research
Researchers studying somatostatin signaling pathway-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor signaling, downstream transcription, or disease phenotypes. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that enable such causal inference.
Contact EDITGENE today to design your custom CRISPR model for somatostatin signaling pathway research.
Frequently Asked Questions About somatostatin signaling pathway
What is GO:0038170 somatostatin signaling pathway?
GO:0038170 is a biological process defined as a G protein-coupled receptor signaling pathway initiated by somatostatin binding to a somatostatin receptor (SSTR), and ending with regulation of a downstream cellular process such as transcription.
What genes are involved in somatostatin signaling pathway?
Key genes include SST (somatostatin ligand), SSTR1-SSTR5 (receptors), and downstream effectors such as NOTCH1, HES1, MUC2, TGFB1, SMAD2/3, and GAD1/GAD2.
How does somatostatin signaling work?
Somatostatin binds to SSTRs, activates Gi/Go proteins, inhibits adenylyl cyclase, and modulates downstream effectors such as ion channels and transcription factors, ultimately regulating secretion, proliferation or gene expression.
What diseases are linked to somatostatin signaling?
Somatostatin signaling is linked to pancreatic cancer EMT, gestational diabetes-induced glucose intolerance in offspring, autism-related social behavior, and gastrointestinal mucus barrier function.
Which receptors mediate somatostatin signaling?
Five somatostatin receptors (SSTR1-SSTR5) mediate the pathway; SSTR5 is specifically linked to colonic MUC2 expression via Notch-Hes1.
How can I study somatostatin signaling with CRISPR?
CRISPR knockout, knock-in, point mutation and overexpression of SST, SSTRs or downstream genes can be used to dissect the pathway in cell and animal models.
What is the role of somatostatin in the brain?
Central somatostatin signaling regulates food intake, neuronal excitability, and social behavior, with implications for autism-spectrum phenotypes.
Does somatostatin affect the gastrointestinal tract?
Yes, somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling, influencing the mucus barrier.
What experimental models are used for somatostatin signaling research?
Common models include SSTR knockout cell lines, pancreatic islet-specific knockout mice, autism mouse models, and intestinal organoids.
How does somatostatin signaling regulate transcription?
Activated SSTRs modulate transcription factors such as Hes1 and Smad proteins, leading to changes in target gene expression like MUC2.
Conclusion
GO:0038170 (somatostatin signaling pathway) is a pleiotropic GPCR pathway that translates somatostatin binding into diverse cellular outcomes, from hormone inhibition to transcriptional regulation of mucus and metabolic genes. Its involvement in pancreatic cancer, gestational diabetes, autism-related behavior and gastrointestinal function makes it a high-value target for mechanistic and translational research. CRISPR-based cell models and functional genomics screens provide powerful tools to dissect receptor-specific and context-dependent functions of this pathway, enabling the discovery of new therapeutic opportunities.
References
- 1. Song S et al.. 2020. Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway.. Biochem Biophys Res Commun 521(4):1070-1076 PMID: 31733832
- 2. Zhu H et al.. 2026. Epigenetically regulated pancreatic GABA-somatostatin signaling underlies gestational diabetes-induced glucose intolerance in offspring.. Sci Transl Med 18(839):eadx8909 PMID: 41779871
- 3. Zhou X et al.. 2023. Somatostatin Inhibited the EMT of Pancreatic Cancer Cells by Mediating the TGF-β/Smad Signaling Pathway.. Discov Med 35(179):1086-1092 PMID: 38058074
- 4. Reisine T. 1995. Somatostatin.. Cell Mol Neurobiol 15(6):597-614 PMID: 8719032
- 6. Stengel A et al.. 2019. Central somatostatin signaling and regulation of food intake.. Ann N Y Acad Sci 1455(1):98-104 PMID: 31237362
- 7. Kossut M et al.. 2018. Somatostatin receptors in the brain.. Postepy Biochem 64(3):213-221 PMID: 30656906
- 8. Borie AM et al.. 2024. Neuropeptide therapeutics to repress lateral septum neurons that disable sociability in an autism mouse model.. Cell Rep Med 5(11):101781 PMID: 39423809
